| Literature DB >> 27746637 |
Zheng Jun Li1, Dae-Kyoung Choi1, Kyung-Cheol Sohn1, Seul Ki Lim1, Myung Im1, Young Lee1, Young-Joon Seo1, Chang Deok Kim1, Jeung-Hoon Lee1.
Abstract
BACKGROUND: Interleukin-17A (IL-17A) is mainly secreted from Th17 cells that are activated by various stimuli including CpG oligodeoxynucleotide, a Toll-like receptor 9 (TLR9) ligand. Recently, it has been demonstrated that keratinocytes play an important role in the pathogenesis of psoriasis.Entities:
Keywords: CpG; Interleukin-17A; Keratinocytes; NF-κB; Psoriasis
Year: 2016 PMID: 27746637 PMCID: PMC5064187 DOI: 10.5021/ad.2016.28.5.579
Source DB: PubMed Journal: Ann Dermatol ISSN: 1013-9087 Impact factor: 1.444
Fig. 1CpG induces interleukin-17A (IL-17A) expression in HaCaT keratinocytes. (A) Cells were treated with 10 µM CpG for the indicated time points, and cytokine expression was assessed by quantitative real-time polymerase chain reaction. (B) After treatment with CpG, medium was collected and IL-17A was determined by ELISA. The mean values±standard deviation are averages of triplicate measurements. *p<0.05 versus time 0 hour. (C) Expression of IL-17A was detected in normal and psoriatic lesional skin tissues by immunohistochemistry. It clearly shows that expression of IL-17A is increased in psoriatic lesional skin compared to normal skin. TNF-α: tumor necrosis factor-α.
Fig. 2CpG induces interleukin-17A (IL-17A) expression via nuclear factor (NF)-κB-dependent way. (A) HaCaT keratinocytes were transduced with 1 multiplicity of infection of NF-κB reporter adenovirus for overnight. Cells were replenished with fresh medium, and then treated with 10 µM CpG for 24 hours. Luciferase assay was performed and data are expressed as fold induction. Data represent the mean±standard deviation (SD) (n=3). *p<0.05. (B) Cells were treated with 10 µM CpG for the indicated time points, then phosphorylated-IκBα (p-IκBα) and CIAP2 were analyzed by Western blot. (C) Cells were pretreated with NF-κB inhibitor Bay-11 (10 ng/ml) or CpG antagonist G-ODN (4 µM) for 30 minutes, then treated with 10 µM CpG for 2 days. Secreted IL-17A was determined by ELISA. The mean values±SD are averages of triplicate measurements. *p<0.05.
Fig. 3Interleukin-17A (IL-17A) secreted from keratinocytes affects IL-22 production in CD4+ T cells. (A) CD4+ T cells were isolated from human blood. After a first round of stimulation with CD3/CD28, CD4+ T cells were treated with conditioned medium obtained from CpG-treated HaCaT keratinocytes (CpG-CM) and/or conditioned medium obtained from CpG-non-treated HaCaT keratinocytes (CTL-CM). For preparation of conditioned medium, HaCaT keratinocytes were treated with 10 µM CpG for 24 hours, then cells were replenished with fresh medium and incubated for a further 24 hours. After collecting the medium, cell debris was discarded by centrifugation and supernatant was used as the conditioned medium. (B) Conditioned medium was neutralized with preincubation with anti-IL-17A antibody. Normal IgG was used as a negative control. Secreted IL-22 was determined by ELISA. The mean values±standard deviation are averages of triplicate measurements. *p<0.05.
Fig. 4Proposed model for the crosstalk between keratinocytes and CD4+ T cells. Keratinocytes recognize the Toll-like receptor 9 (TLR9) agonist and then release interleukin-17A (IL-17A) in a nuclear factor (NF)-κB-dependent way. Secreted IL-17A activates CD4+ T cells to produce IL-22, which in turn affects keratinocytes pathogenically.